Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion

References

• Klein R, Klein BEK, Moss SE, et al. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Transactions of the American Ophthalmological Society 2000;98:133–143
   PubMedGoogle Scholar
• Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: The Blue Mountains Eye Study. Archives of Ophthalmology 1996;114(10):1243–1247
   PubMed Web of Science ®Google Scholar
• Awdeh RM, Elsing SH, Deramo VA, et al. Vision-related quality of life in persons with branch retinal vein occlusion (BRVO) using the 25-item NIE Visual Function Questionnaire. Br J Ophthalmol 2010;94:319–323
   PubMed Web of Science ®Google Scholar
• Petrella RJ, Blouin J, Davies B, and Barbeau M. Incidence and characteristics of patients with visual impairment due to macular edema secondary to retinal vein occlusion in a representative Canadian cohort. J Ophthalmol 2012;2012:72--77
   Google Scholar
• The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98(3):271–282
   PubMed Web of Science ®Google Scholar
• Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: Results after 12 months and multiple regression analysis. Retina 2009;29:1242–1248
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Szurman P, Bartz-Schmidt K. Recommendation for the procedure of intravitreal injections of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 2005;222:390–395
   PubMed Web of Science ®Google Scholar
• The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115–1128
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22:42–48
   PubMed Web of Science ®Google Scholar
• Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025–1032
   PubMed Web of Science ®Google Scholar
• Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508–512
   PubMed Web of Science ®Google Scholar
• Rosefield PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336–339
   PubMed Web of Science ®Google Scholar
• Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. Available at http://www.nice.org.uk/guidance/TA229 [Last accessed September 2013]
   Google Scholar
• Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287–290
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Leitritz M, Gelisken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27–33
   PubMed Web of Science ®Google Scholar
• Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351–355
   PubMed Web of Science ®Google Scholar
• Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: A prospective study. Br J Ophthalmol 2008;92:518–522
   PubMed Web of Science ®Google Scholar
• Dempke WC, Heinemann V. Resistance to EGF-R (erB-1) and VEGF-R modulating agents. Eur J Cancer 2009;45:1117–1128
   PubMed Web of Science ®Google Scholar
• Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012;118:3455–3467
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417–427
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Dhillon J, Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2011;9:101–110
   PubMedGoogle Scholar
• Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: Results of the pan American collaborative retina study group at 24 months. Retina 2010;30(7):1002–1011
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Szurman P, Feltgen N, et al. Retinal Vein Occlusion Study Group Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011;249:183–192
   PubMed Web of Science ®Google Scholar
• Chung EJ, Hong YT, Lee SC, et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241–1247
   PubMed Web of Science ®Google Scholar
• Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 2008;223:124–127
   PubMed Web of Science ®Google Scholar
• Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: Tachyphylaxis or tolerance? Br J Ophthalmol 2012;96:1–2
   PubMed Web of Science ®Google Scholar
• Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2012;22(4):607–614
   PubMed Web of Science ®Google Scholar
• Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular edema secondary to retinal vein occlusion: twelve-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452–526
   PubMed Web of Science ®Google Scholar